TXG — 10X Genomics Income Statement
0.000.00%
Last trade - 00:00
- $2.70bn
- $2.32bn
- $618.73m
- 67
- 24
- 25
- 32
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 246 | 299 | 490 | 516 | 619 |
Cost of Revenue | |||||
Gross Profit | 185 | 240 | 416 | 396 | 409 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 276 | 835 | 543 | 684 | 884 |
Operating Profit | -30.6 | -536 | -52.3 | -168 | -265 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -31 | -534 | -53.7 | -162 | -249 |
Provision for Income Taxes | |||||
Net Income After Taxes | -31.3 | -543 | -58.2 | -166 | -255 |
Net Income Before Extraordinary Items | |||||
Net Income | -31.3 | -543 | -58.2 | -166 | -255 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -31.3 | -543 | -58.2 | -166 | -255 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.325 | -5.34 | -0.528 | -1.46 | -1.6 |